Literature DB >> 25896686

Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.

Paula Virginia Michelon Toledo1, Ayrton Alves Aranha Junior2, Lavinia Nery Arend3, Vanessa Ribeiro4, Alexandre Prehn Zavascki4, Felipe Francisco Tuon5.   

Abstract

This study evaluated the efficacy of tigecycline (TIG), polymyxin B (PMB), and meropenem (MER) in 80 rats challenged with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae infection. A time-kill assay was performed with the same strain. Triple therapy and PMB+TIG were synergistic, promoted 100% survival, and produced negative peritoneal cultures, while MER+TIG showed lower survival and higher culture positivity than other regimens (P = 0.018) and was antagonistic. In vivo and in vitro studies showed that combined regimens, except MER+TIG, were more effective than monotherapies for this KPC-producing strain.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25896686      PMCID： PMC4468658          DOI： 10.1128/AAC.00323-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Surveillance programme for multidrug-resistant bacteria in healthcare-associated infections: an urban perspective in South Brazil.

Authors:  P V M Toledo; L N Arend; M Pilonetto; J C Costa Oliveira; K R Luhm
Journal:  J Hosp Infect       Date:  2012-02-29       Impact factor: 3.926

2.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.

Authors:  Spyros Pournaras; Georgia Vrioni; Evangelia Neou; John Dendrinos; Evangelia Dimitroulia; Aggeliki Poulou; Athanassios Tsakris
Journal:  Int J Antimicrob Agents       Date:  2011-01-13       Impact factor: 5.283

Review 4.  Efficacy and safety of tigecycline: a systematic review and meta-analysis.

Authors:  Dafna Yahav; Adi Lador; Mical Paul; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2011-06-18       Impact factor: 5.790

5.  Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.

Authors:  O Zarkotou; S Pournaras; P Tselioti; V Dragoumanos; V Pitiriga; K Ranellou; A Prekates; K Themeli-Digalaki; A Tsakris
Journal:  Clin Microbiol Infect       Date:  2011-05-20       Impact factor: 8.067

6.  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Authors:  Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.

Authors:  Mario Tumbarello; Pierluigi Viale; Claudio Viscoli; Enrico Maria Trecarichi; Fabio Tumietto; Anna Marchese; Teresa Spanu; Simone Ambretti; Francesca Ginocchio; Francesco Cristini; Angela Raffaella Losito; Sara Tedeschi; Roberto Cauda; Matteo Bassetti
Journal:  Clin Infect Dis       Date:  2012-07-02       Impact factor: 9.079

8.  Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach; Marie Synnestvedt; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254

9.  Risk factors for KPC-producing Klebsiella pneumoniae bacteremia.

Authors:  Felipe F Tuon; Jaime L Rocha; Paula Toledo; Lavinia N Arend; Camila H Dias; Talita M Leite; Sergio R Penteado-Filho; Marcelo Pilonetto; Alexandre P Zavascki
Journal:  Braz J Infect Dis       Date:  2012-09-12       Impact factor: 1.949

Review 10.  Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.

Authors:  J M Entenza; P Moreillon
Journal:  Int J Antimicrob Agents       Date:  2009-01-21       Impact factor: 5.283
View more
  10 in total

1.  Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection.

Authors:  Sheng Bi; Xin Yao; Cheng Huang; Xia Zheng; Tianming Xuan; Jifang Sheng; Kaijin Xu; Beiwen Zheng; Qing Yang
Journal:  Infection       Date:  2019-02-07       Impact factor: 3.553

2.  Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.

Authors:  John K Diep; David M Jacobs; Rajnikant Sharma; Jenna Covelli; Dana R Bowers; Thomas A Russo; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Synergistic activity of synthetic N-terminal peptide of human lactoferrin in combination with various antibiotics against carbapenem-resistant Klebsiella pneumoniae strains.

Authors:  P Morici; W Florio; C Rizzato; E Ghelardi; A Tavanti; G M Rossolini; A Lupetti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-03       Impact factor: 3.267

Review 4.  The rapid spread of carbapenem-resistant Enterobacteriaceae.

Authors:  Robert F Potter; Alaric W D'Souza; Gautam Dantas
Journal:  Drug Resist Updat       Date:  2016-09-19       Impact factor: 18.500

5.  In vitro research of combination therapy for multidrug-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Leiming Sun; Jing Sun; Shibiao Ding
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

Review 6.  Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation.

Authors:  Callum J Cooper; Shazeeda Koonjan; Anders S Nilsson
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-19

7.  Effects of Zinc Oxide Nanoparticles Synthesized Using Aspergillus niger on Carbapenem-Resistant Klebsiella pneumonia In Vitro and In Vivo.

Authors:  Elsayim Rasha; Manal M Alkhulaifi; Monerah AlOthman; Ibrahim Khalid; Elnagar Doaa; Khatab Alaa; Manal A Awad; Mohnad Abdalla
Journal:  Front Cell Infect Microbiol       Date:  2021-11-16       Impact factor: 5.293

Review 8.  When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  Clin Lab Med       Date:  2019-06-12       Impact factor: 1.935

Review 9.  Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods.

Authors:  Chang-Ro Lee; Jung Hun Lee; Kwang Seung Park; Young Bae Kim; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Microbiol       Date:  2016-06-13       Impact factor: 5.640

10.  In vitro and in vivo antibacterial activity assays of carvacrol: A candidate for development of innovative treatments against KPC-producing Klebsiella pneumoniae.

Authors:  Gleyce Hellen de Almeida de Souza; Joyce Alencar Dos Santos Radai; Marcia Soares Mattos Vaz; Kesia Esther da Silva; Thiago Leite Fraga; Leticia Spanivello Barbosa; Simone Simionatto
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.